EU-GMP Chapter 8 has been in operation since 1 March 2015, and it is the chapter an importer's auditor opens after something has already gone wrong. A German pharmacy reports a damaged seal. A retest shows moisture above specification. A patient-facing distributor flags foreign matter in a jar. Each one lands on the importer first, then travels back to the Canadian Licensed Producer that grew the batch.
EU-GMP Chapter 8 complaints, quality defects and product recalls rules require a written system to record, assess and investigate every complaint, apply quality risk management to each decision, report confirmed quality defects to the competent authorities in a timely manner, and recall product promptly at any time. Your EU importer carries the legal duty, but the evidence it relies on comes from your batch, distribution and investigation records.
That split is where Canadian LPs get caught. The importer has 31 paragraphs to satisfy, and almost every one of them depends on records held at your Canadian facility.
What EU-GMP Chapter 8 requires from a cannabis supplier
The European Commission published the revised chapter on 13 August 2014 and gave manufacturers about six and a half months to comply. The main change was to make quality risk management, the method set out in ICH Q9(R1), the basis for every complaint, defect and recall decision. Our guide to quality risk management under ICH Q9(R1) covers the scoring tools. Medical cannabis flower entering the EU is handled as a medicinal product under EU-GMP, so this text applies to your flower exactly as it applies to a tablet.
Chapter 8 is short. It runs to 31 numbered paragraphs in five parts, and auditors tend to test each part with a different document.
| Part | Paragraphs | What an auditor asks to see |
|---|---|---|
| Personnel and organisation | 8.1 to 8.4 | Named defect owners, independent of sales |
| Complaint handling procedures | 8.5 to 8.9 | Complaint SOP and a populated complaint log |
| Investigation and decision-making | 8.10 to 8.15 | Risk-based decisions, documented in real time |
| Root cause analysis and CAPA | 8.16 to 8.19 | Root cause records and defect trend reviews |
| Recalls and risk-reducing actions | 8.20 to 8.31 | Recall SOP, distribution records, recall test results |
The people rule in paragraph 8.1
The people who manage complaints and decide on recalls must be trained, experienced and independent of sales and marketing unless otherwise justified. If the Qualified Person who certified the batch isn't on that team, they must be told formally and in a timely way about any investigation or recall. In a cross-border chain, that QP usually sits with your importer, and the EU QP batch release process explains why their signature depends on your records.
The contract rule in the Principle
Where activities are outsourced, a contract must set out each party's role in assessing a defect, deciding on action, sharing information and carrying out risk-reducing measures, plus how to reach each party's responsible person. The rules for those contracts sit in EU-GMP Chapter 7 outsourced activities. For a Canadian exporter, that contract is usually the quality agreement with your EU importer. If it says nothing about defect notification windows, it fails Chapter 8 before any complaint arrives.
How a cannabis complaint becomes a quality defect investigation
Paragraph 8.5 requires every complaint to be documented and assessed to decide whether it signals a potential quality defect. Not every complaint is one. A late shipment is a service complaint. A suspected adverse event goes to the people who handle those, under paragraph 8.7. Mould, off odour, moisture out of specification, a broken tamper seal or a potency result that diverges from your certificate of analysis are quality defect signals, and they trigger the investigation procedure in paragraph 8.9.
Paragraph 8.6 adds a check most LPs skip: whether the complaint relates to falsification. Flower that is relabelled under an importer's article number is harder to trace. Ask whether the product in the complaint is really yours before you investigate it as yours.
The nine points every investigation procedure must cover
- A description of the reported defect
- Its extent, including retention sample checks and a review of batch production, certification and distribution records
- Whether to request a sample or the return of the product, and how to evaluate it
- A risk assessment based on severity and extent
- The decision process for recalls or other risk-reducing actions
- The impact of any recall on patient supply in each affected market
- Internal and external communications
- The probable root cause
- Corrective and preventive actions, with an effectiveness check
The second point is where your retained material earns its keep. A sealed retention sample from the same lot lets you test what left your facility against what reached the complainant. Our guide to cannabis retention samples under Annex 19 covers quantities and storage. When the complaint is a potency gap, start with the method differences explained in why EU retest numbers differ from your COA before you call it a defect.
Other batches, root cause and the human error trap
Paragraph 8.11 asks you to check other batches that could share the defect. For flower, that means lots from the same grow room, the same harvest split into several lots, or the same drying run. Paragraph 8.17 then limits a convenient answer. If you blame human error, you must justify it formally and show that no process or system failure sat behind it. Our guide to deviation and CAPA management shows how to write a root cause an auditor will accept.
An investigation closed as "operator error, retrained" with no system review doesn't meet paragraph 8.17, and auditors will ask what changed in the process.
Chapter 8 recalls compared with Health Canada recall rules
Paragraph 8.21 treats any retrieval of product from the distribution network after it has been placed on the market, because of a quality defect, as a recall. Paragraph 8.22 says recall operations must be capable of starting promptly and at any time, sometimes before the root cause is known. Canadian rules from Health Canada already ask for something similar. Section 46 of the Cannabis Regulations requires a system of control that permits the rapid and complete recall of every lot or batch sold or distributed, plus a recall simulation at least once every 12 months.
The two systems overlap on recall capability but differ on testing, records and authority contact.
| Element | EU-GMP Chapter 8 | Cannabis Regulations |
|---|---|---|
| Recall capability | Start promptly, at any time (8.22) | Rapid and complete recall of every lot (s. 46(1)) |
| Testing the system | Periodic, in and out of office hours (8.30) | Recall simulation every 12 months (s. 46(2)) |
| Distribution records | Customer contacts inside and outside working hours, including exports (8.23) | Records of cannabis sold, distributed or exported |
| Authority contact | All concerned authorities informed in advance of a recall (8.26) | Report to Health Canada before notifying customers |
| Recalled stock | Segregated, formal disposition, rework discussed with the authority (8.28) | Handled under the licence holder's recall procedure |
| Closure | Final report reconciling delivered and recovered quantities (8.29) | Final report to Health Canada after completion |
Two rows cause most of the trouble. The first is paragraph 8.23, which wants after-hours contact details for every directly supplied customer. A recall that can only start on Monday morning fails it. The second is paragraph 8.30, which asks you to test recall arrangements outside office hours too. A section 46 simulation run at 10 a.m. on a Tuesday meets the Canadian rule, but it tells an EU importer nothing about a Saturday night recall.
The Health Canada reporting sequence is covered in detail in cannabis recall requirements for Canadian LP exporters. Run both procedures from one recall SOP, with a separate EU branch, so you aren't writing two responses under one deadline.
The 5-step Chapter 8 readiness file for Canadian LPs
This sequence builds a file your importer can drop straight into their supplier qualification. Run it ahead of your next importer audit.
1. Map your complaint SOP to paragraphs 8.5 to 8.9
List the nine investigation points and point each one to a step, a form or a role. Add a falsification check and a routing step for suspected adverse events.
2. Name the defect team and the escalation path
Name a quality lead who is independent of sales, a deputy, and the importer's QP contact. Put notification windows in the quality agreement as a set number of hours.
3. Push distribution records one step past the loading dock
Record every consignee with after-hours contacts, lots and quantities. Require the importer to keep onward records against your lot numbers, which is the gap described in our guide to cannabis batch traceability.
4. Test the recall outside office hours
Run your annual section 46 simulation on an export lot, start it after hours, and time how long it takes to reconcile delivered against recoverable quantities.
5. Trend every defect, every quarter
Paragraph 8.19 requires regular trend analysis. Feed the results into your product quality review and your Chapter 9 self-inspection, so recurring problems surface before an auditor finds them.
A complaint log with zero entries after a year of export shipments will make an EU auditor ask whether complaints are being recorded at all.
AlphaLeaf is a Health Canada Licensed Producer in Montreal, growing indoor, hand-trimmed flower from refined genetics. We hold export authorisation under the Cannabis Act, test every batch at an ISO/IEC 17025 accredited laboratory, and keep the full batch traceability and quality records that EU medical importers need for their complaint and recall systems.
Your importer's Chapter 8 file depends on your records. Start with step one this quarter. If you're assessing a Canadian supply partner for the EU medical channel, talk to the AlphaLeaf team about our quality documentation.
Frequently Asked Questions
What is EU-GMP Chapter 8?
EU-GMP Chapter 8 is the chapter of the EU GMP Guide that covers complaints, quality defects and product recalls. The current text was published on 13 August 2014 and came into operation on 1 March 2015. It requires written procedures to record, assess and investigate complaints, apply quality risk management to decisions, report confirmed quality defects to competent authorities and recall product promptly.
Does EU-GMP Chapter 8 apply to Canadian cannabis producers?
It applies to your flower once it enters the EU medical channel. The EU importer holds the legal obligation, but it can only meet Chapter 8 with your batch records, retention samples, distribution records and investigation support, so importers write those duties into the quality agreement and audit you against them.
Is every cannabis complaint a quality defect under Chapter 8?
No. Paragraph 8.5 requires every complaint to be documented and assessed, but only some indicate a potential quality defect. Service issues such as late delivery are not defects, and suspected adverse events go to the team that handles those under paragraph 8.7. Mould, moisture out of specification, broken seals and potency gaps against the certificate of analysis do trigger a defect investigation.
Who reports a cannabis quality defect to EU authorities?
Under paragraph 8.15 the manufacturer reports quality defects that may lead to a recall or an abnormal restriction in supply to the marketing authorisation holder and all concerned competent authorities. In most cannabis import chains that is the EU importer holding the manufacturing and import authorisation, which is why the Canadian supplier must notify the importer quickly and in writing.
How often should recall arrangements be tested under Chapter 8?
Paragraph 8.30 asks for periodic evaluation, covering both office-hour and out-of-office-hour situations, with consideration of mock recalls. It does not set a fixed frequency. Canadian licence holders already run a recall simulation at least once every 12 months under section 46 of the Cannabis Regulations, and running that simulation after hours on an export lot covers both requirements.
Can a recalled cannabis batch be reworked under EU-GMP Chapter 8?
Only with a documented rationale discussed with the relevant competent authority. Paragraph 8.28 requires recalled product to be segregated in a secure area pending a formal, documented disposition, and any reworked batch must be assessed for the shelf life it has left before it can return to market.
